Former President of the Philippines, Joseph Estrada, Among the Many COVID-19 Patients Receiving Leronlimab Under CSP in the Philippines
April 19, 2021 06:00 ET | Source: CytoDyn Inc. CytoDyn Inc. Vancouver, Washington, UNITED STATES
CytoDyn is following all patients treated with leronlimab under CSP and will provide additional information when available and authorized for release
VANCOUVER, Washington, April 19, 2021 (GLOBE NEWSWIRE)
CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company ), a late-stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with potential multiple therapeutic indications, announced today former President of the Philippines, Joseph Estrada, was administered leronlimab under Compassionate Special Permit (CSP), among other medication, as a therapeutic for COVID-19. Mr. Estrada remains hospitalized and news reports indicate he may be transferred from ICU to a regular ho
CytoDyn raises another $25M for Vyrologix development in second covertable debt offering this month
The note may be converted at the option of the investor into shares of the common stock at a price of $10 per share It has raised more than $50 million in the past three weeks and roughly $500 million in the company’s history
CytoDyn Inc (OTCQB:CYDY) announced that it has completed an additional potentially non-dilutive convertible debt offering with an institutional investor, which provides $25 million of immediately available capital.
The note has a two-year maturity, bears interest at the rate of 10% annually, and is secured by all assets of the company, excluding its intellectual property. The note may be converted at the option of the investor into shares of the common stock at a price of $10 per share, the company said.
CytoDyn Completes $28.5 Million Convertible Note Financing with Conversion Rate at $10.00 Per Share Without Warrants
Company Achieves Total Financing in April of $57 Million
VANCOUVER, Washington, April 22, 2021 (GLOBE NEWSWIRE)
CytoDyn Inc. (OTC.QB: CYDY), (“CytoDyn” or the “Company”), a late-stage biotechnology company developing leronlimab (Vyrologix or PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today it completed an additional potentially non-dilutive convertible debt offering with an institutional investor, which provides $25 million of immediately available capital. The note has a two-year maturity, bears interest at the rate of 10% per annum and is secured by all assets of the Company, excluding its intellectual property. The note may be converted at the option of the investor into shares of the Company’s common stock at a conversion price of $10.00 per share.
CytoDyn CEO talks through its two recent convertible debt financing efforts of $50M
CytoDyn Inc (OTCQB:CYDY) CEO Nader Pourhassan tells Proactive it has completed an additional potentially non-dilutive convertible debt offering with an institutional investor, which provides $25 million of immediately available capital. Earlier this month, the company completed a similar convertible debt offering, also worth $25 million. Pourhassan talked through how the group will use the $50M, focusing on three key indications: COVID-19, HIV, and oncology.
Quick facts: CytoDyn Inc.
CytoDyn Inc submits manufacturing section of interim order application for leronlimab as coronavirus (COVID-19) treatment to Health Canada proactiveinvestors.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from proactiveinvestors.com Daily Mail and Mail on Sunday newspapers.